News | April 01, 2026
Merck completes acquisition of JSR Life Sciences’ chromatography business
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Subscribe To Our Newsletter & Stay Updated
